Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018) [0.03%]
蛋白酪氨酸磷酸酶1B(PTP1B)抑制剂作为潜在抗糖尿病药物的专利综述(2015-2018)
Hidayat Hussain,Ivan R Green,Ghulam Abbas et al.
Hidayat Hussain et al.
Introduction: Protein tyrosine phosphatase 1B (PTP1B) inhibition has been recommended as a crucial strategy to enhance insulin sensitivity in various cells and this fact is supported by human genetic data. PTP1B inhibitors improve the sensi...
Paolo Guglielmi,Simone Carradori,Cristina Campestre et al.
Paolo Guglielmi et al.
Introduction: Glaucoma is one of the main leading causes of irreversible blindness in the world. The treatment of this disease relies on the use of drugs able to reduce/control the intraocular pressure (IOP), one of the main risk factors fo...
Paolo Guglielmi,Simone Carradori,Cristina Campestre et al.
Paolo Guglielmi et al.
Introduction: Glaucoma is one of the main leading causes of irreversible blindness in the world. The treatment of this disease relies on the use of drugs able to reduce/control the intraocular pressure (IOP), one of the main risk factors fo...
Ruo-Jun Man,Ya-Liang Zhang,Ai-Qin Jiang et al.
Ruo-Jun Man et al.
Introduction: RAF kinase inhibitors block and regulate RAS/RAF/MEK/ERK signaling, which is a key to tumor treatment. At present, although RAF kinase inhibitors have good efficacy, there are few such drugs with low toxicity, and thus, it is ...
Combretastatin-based compounds with therapeutic characteristics: a patent review [0.03%]
一类具有治疗作用的 Combretastatin 化合物的专利分析与综述
Lalit Mohan Nainwal,Mohammad Mumtaz Alam,Mohammad Shaquiquzzaman et al.
Lalit Mohan Nainwal et al.
Introduction: Combretastatins represent a potent class of phenolic-stilbene natural products that function as colchicine binding site inhibitors of tubulin polymerization and have been advanced as promising anticancer lead compounds. Among ...
Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018) [0.03%]
新型抗癌药物——微管抑制剂(2013-2018)专利综述
Kashif Haider,Shaik Rahaman,M Shahar Yar et al.
Kashif Haider et al.
Introduction: About 20 patents have been published from 2013 to 2018 for developing advanced cancer therapeutics by targeting tubulin polymerization. Currently, there are several tubulin inhibitors that are in the drug development pipeline ...
Inder Pal Singh,Furkan Ahmad,Dattatraya Dinkar Gore et al.
Inder Pal Singh et al.
Introduction: Seabuckthorn (SBT) has received worldwide attention for therapeutic, nutraceutical and cosmetic purposes. It is used for the treatment of a number of diseases. Hundreds of commercial products containing SBT are available in th...
Therapeutic modulation of retinoid X receptors - SAR and therapeutic potential of RXR ligands and recent patents [0.03%]
维A酸X受体的治疗调节作用-维A酸X受体配体的结构活性关系及治疗潜能和最近专利的发展状况
Simone Schierle,Daniel Merk
Simone Schierle
Introduction: Retinoid X receptor (RXR) agonists have a limited role in cancer therapy with bexarotene and alitretinoin as approved drugs but their use is limited by adverse effects. Several evidence from in vitro, in vivo, and small clinic...
Drug prices and trends before and after requesting compulsory licenses: the Ecuadorian experience [0.03%]
厄瓜多尔强制许可的药品价格及趋势研究
Esteban Ortiz-Prado,Gabriel Cevallos-Sierra,Enrique Teran et al.
Esteban Ortiz-Prado et al.
Introduction: The Ecuadorian Institute of Intellectual Property (IEPI) granted several compulsory licenses between 2011 and 2017. In 2009, the President of Ecuador signed a decree that was intended to facilitate the request of compulsory li...
Martin Perez-Santos,Maricruz Anaya-Ruiz,Jorge Cebada et al.
Martin Perez-Santos et al.
Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of ...